In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa.

BMC Research Notes
Nahid H AhmedAnwar A Hoosen

Abstract

The presence of multi-drug resistant Acinetobacter baumannii raises a big therapeutic challenge in our hospital. Tigecycline, a new glycylcycline with expanded broad spectrum of activity against multi-drug resistant organisms was recently licensed in South Africa. The aim of this study was to evaluate the in vitro activity of tigecycline against carbapenem resistant A. baumannii complex. Consecutive clinical isolates of carbapenem resistant A. baumannii complex were collected between February and July 2010. Species identification and susceptibility testing was performed by Vitek-2 colorimetric compact system with Advanced Expert System (AES). Strains were tested for carbapenemase production by the modified Hodge test, according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. A total of 232 carbapenem resistant clinical isolates of A. baumannii complex were collected over the six months study period; 217 (93.5%) of these were modified Hodge test positive. All isolates were susceptible to colistin and 174 (78%) susceptible to amikacin whilst 20 (9%) were susceptible to ciprofloxacin. For tigecycline 169 (75.8%) were fully susceptible, 37 (16.6%) intermediately resistant and only 17 (7.6%) were fully resistan...Continue Reading

References

Sep 20, 2006·Clinical Therapeutics·Thien-Ly DoanPaul F Riska
Apr 26, 2008·The Journal of Antimicrobial Chemotherapy·Drosos E KarageorgopoulosMatthew E Falagas
Jul 16, 2008·Clinical Microbiology Reviews·Anton Y PelegDavid L Paterson
Dec 17, 2008·International Journal of Antimicrobial Agents·Jien-Wei LiuPo-Ren Hsueh
Nov 26, 2009·Expert Opinion on Pharmacotherapy·José MolinaJerónimo Pachón
Nov 4, 2010·Indian Journal of Pathology & Microbiology·Anand ManoharanDilip Mathai
Jun 21, 2011·The Journal of Antimicrobial Chemotherapy·Dafna YahavLeonard Leibovici
Jun 23, 2011·Infection and Drug Resistance·Mary L TownsendRichard H Drew

❮ Previous
Next ❯

Citations

Feb 24, 2015·Current Medical Research and Opinion·Abed Zahedi Bialvaei, Hossein Samadi Kafil
Dec 3, 2014·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Camila RizekSilvia F Costa
Feb 16, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rebecca LesterNicholas A Feasey
Apr 15, 2018·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Esther Eyram AgobaSabiha Yusuf Essack
Jan 7, 2021·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Sajad YaghoubiFarajolah Maleki
Apr 10, 2021·Indian Journal of Medical Microbiology·Noel-David NogbouAndrew Munyalo Musyoki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.